Geriatric Pharmacology - Pharmacology

SECTION 1

Historical Context & Motivation

For most of modern medicine's history, drug dosing guidelines were derived from studies conducted predominantly in young, healthy adult males. The consequences of this gap became starkly apparent as life expectancy increased throughout the twentieth century and clinicians observed that older patients experienced disproportionately higher rates of adverse drug reactions (ADRs). The emergence of geriatric pharmacology as a distinct discipline arose from the recognition that age-related physiological changes fundamentally alter how drugs behave in the body, necessitating tailored therapeutic strategies for patients aged 65 and older.

1909 • Nascher Coins 'Geriatrics'

Ignatz Nascher, a New York physician, publishes the first English-language textbook on diseases of old age and coins the term geriatrics, laying the conceptual groundwork for age-specific medicine.

1966 • Clinical Pharmacokinetics Emerges

Seminal studies by Brodie and others establish clinical pharmacokinetics as a field, enabling researchers to quantify how drug absorption, distribution, metabolism, and excretion differ across populations—including the elderly.

1991 • Beers Criteria Published

Mark Beers publishes the original Beers Criteria, the first explicit list of potentially inappropriate medications (PIMs) for older adults, which becomes a cornerstone of geriatric prescribing safety.

2008 • STOPP/START Criteria

European researchers introduce the STOPP/START screening tools, offering systems-based criteria for identifying medications to stop and therapeutic omissions to start in older patients, complementing the Beers list.

2019 • Updated AGS Beers Criteria

The American Geriatrics Society releases an updated Beers Criteria reflecting contemporary evidence, reinforcing the ongoing evolution of evidence-based geriatric pharmacotherapy.

Today, adults aged 65 and older constitute approximately 16% of the U.S. population yet consume over 30% of all prescription medications. This demographic reality, combined with the prevalence of polypharmacy (concurrent use of five or more medications) and multimorbidity, makes geriatric pharmacology one of the most clinically urgent areas in modern healthcare. The central question the field addresses is deceptively simple: how must we adjust our pharmacological approach when the body processing a drug has been reshaped by decades of aging?

SECTION 2

Core Principles of Geriatric Pharmacology

Geriatric pharmacology rests on the understanding that aging produces predictable—though individually variable—changes in organ function, body composition, and homeostatic reserve. These changes alter every phase of a drug's journey through the body: pharmacokinetics (what the body does to the drug) and pharmacodynamics (what the drug does to the body). Mastering these twin pillars allows clinicians to anticipate risks and individualize therapy for older adults.

Altered Pharmacokinetics

Age-related declines in renal clearance, hepatic metabolism, and changes in body composition shift drug concentrations—often upward—necessitating dose adjustments to avoid toxicity.

Altered Pharmacodynamics

Receptor sensitivity, signal transduction efficiency, and homeostatic counter-regulation change with age. Older adults may show exaggerated or blunted responses to the same plasma drug concentration.

Polypharmacy & Drug Interactions

Multiple comorbidities lead to multiple medications, exponentially increasing the risk of drug–drug interactions, duplicative pharmacology, and prescribing cascades.

Reduced Physiological Reserve

Diminished organ reserve means older patients have less capacity to compensate for drug-induced perturbations, making ADRs more severe and recovery slower.

Start Low, Go Slow

The guiding principle of geriatric prescribing: initiate therapy at the lowest effective dose, titrate slowly, and reassess frequently to balance efficacy against the heightened risk of harm.

✦

KEY TAKEAWAY

Think of the aging body as an older highway system: the roads are narrower (reduced renal/hepatic clearance), the on-ramps are slower (delayed absorption), and the bridges have lower weight limits (diminished organ reserve). A truck—the drug—that travels safely on a new interstate may overload this aging infrastructure. Geriatric pharmacology is essentially re-engineering the cargo to fit the road, adjusting the dose, frequency, and drug selection so the therapeutic payload reaches its destination without collapsing the bridge.

SECTION 3

Pharmacokinetic Changes with Aging — Visual Overview

This diagram maps the four ADME phases—Absorption, Distribution, Metabolism, and Excretion—showing the specific physiological changes that occur in older adults and their clinical consequences. The net effect is consistently higher effective drug concentrations and prolonged drug action.

The diagram above illustrates how each ADME phase is affected by aging. In the absorption phase, elevated gastric pH and reduced splanchnic blood flow can alter the ionization and uptake of orally administered drugs, though overall bioavailability remains relatively preserved for most agents. The more clinically significant changes occur downstream. Increased adipose tissue relative to lean body mass expands the volume of distribution (V_d) for lipophilic drugs such as benzodiazepines and amiodarone, resulting in prolonged half-lives and drug accumulation. Simultaneously, decreased serum albumin increases the unbound (pharmacologically active) fraction of highly protein-bound drugs like warfarin and phenytoin. In the liver, reduced hepatic mass, diminished blood flow, and decreased Phase I (CYP450-mediated) oxidative reactions slow the biotransformation of many drugs, while Phase II conjugation reactions remain relatively intact. Finally, the kidneys represent the most predictable and clinically impactful site of age-related decline: the glomerular filtration rate (GFR) decreases approximately 1 mL/min per year after age 40, profoundly affecting the clearance of renally eliminated drugs such as digoxin, lithium, and aminoglycosides.

SECTION 4

Quantitative Framework — Key Equations

While geriatric pharmacology is often presented qualitatively, several fundamental pharmacokinetic equations help clinicians quantify age-related changes and make informed dose adjustments. Understanding these relationships is essential for safe prescribing in older adults.

COCKCROFT-GAULT EQUATION

CrCl = [(140 − age) × weight (kg)] / [72 × S_Cr (mg/dL)] (× 0.85 if female)

Where CrCl = estimated creatinine clearance (mL/min), age = patient age in years, weight = actual body weight in kg, and S_Cr = serum creatinine concentration. This equation directly incorporates age, demonstrating how renal clearance declines predictably with aging. Note that muscle wasting in the elderly may produce deceptively normal serum creatinine despite significantly impaired GFR.

HALF-LIFE RELATIONSHIP

t½ = (0.693 × V_d) / CL

Where t½ = elimination half-life, V_d = volume of distribution, and CL = total body clearance. In geriatric patients, V_d often increases for lipophilic drugs while CL decreases due to hepatic and renal decline—both changes drive t½ upward, meaning the drug stays active in the body longer.

STEADY-STATE CONCENTRATION

C_ss = (F × Dose) / (CL × τ)

Where C_ss = average steady-state plasma concentration, F = bioavailability, and τ = dosing interval. When CL is reduced in elderly patients, maintaining the same dose and interval yields a higher C_ss—the pharmacokinetic basis for the 'start low, go slow' principle.

⚠

Clinical Pearl

Serum creatinine alone is a poor indicator of renal function in older adults. An 82-year-old woman weighing 50 kg with a serum creatinine of 1.0 mg/dL may appear to have 'normal' renal function, but the Cockcroft-Gault equation reveals a CrCl of only ≈ 34 mL/min—indicating moderate renal impairment requiring dose reduction for many drugs.

SECTION 5

High-Risk Drug Classes & the Beers Criteria

Certain drug classes pose disproportionate risks in geriatric patients due to the pharmacokinetic and pharmacodynamic shifts discussed above. The American Geriatrics Society (AGS) Beers Criteria provides an evidence-based framework for identifying potentially inappropriate medications (PIMs) in older adults. Understanding why specific classes appear on this list reinforces the physiological principles underlying geriatric pharmacology.

This diagram categorizes six high-risk drug classes flagged by the Beers Criteria along with the specific physiological vulnerabilities each class exploits in older adults. The lower panel illustrates a classic prescribing cascade, in which an ADR from one drug is misinterpreted as a new condition, triggering a chain of additional medications.

Drug Class	Key Age-Related Risk	Safer Alternative
Long-acting benzodiazepines (diazepam, chlordiazepoxide)	Prolonged sedation, cognitive impairment, falls, hip fractures	Short-acting benzodiazepine (lorazepam) at low dose, or non-benzodiazepine strategies (CBT-I for insomnia)
First-generation antihistamines (diphenhydramine)	Strong anticholinergic effects: confusion, dry mouth, urinary retention, constipation	Second-generation antihistamines (cetirizine, loratadine)
Non-selective NSAIDs (chronic use)	GI hemorrhage, acute kidney injury, fluid retention, exacerbation of heart failure	Topical NSAIDs, acetaminophen (with hepatic dose limits), or non-pharmacological pain management
Glyburide (long-acting sulfonylurea)	Prolonged severe hypoglycemia due to active metabolites accumulating with decreased renal clearance	Glipizide (shorter-acting), metformin (with GFR monitoring), or DPP-4 inhibitors
Digoxin (>0.125 mg/day)	Narrow therapeutic index; decreased renal clearance leads to accumulation, toxicity (arrhythmias, nausea, visual changes)	Low-dose digoxin (≤0.125 mg/day) with serum level monitoring; target concentration 0.5–0.9 ng/mL

Selected PIMs from the AGS Beers Criteria with geriatric-appropriate alternatives

SECTION 6

Worked Example — Dose Adjustment for Renal Impairment

An 80-year-old male patient weighing 68 kg is admitted for atrial fibrillation. His serum creatinine is 1.4 mg/dL. The physician plans to start digoxin, which is 85% renally excreted. The standard adult maintenance dose is 0.25 mg/day. Using the Cockcroft-Gault equation, determine whether this dose is appropriate, and if not, calculate an adjusted dose.

Digoxin Dose Adjustment in an Elderly Patient

1
Step 1 — Estimate Creatinine Clearance

Apply the Cockcroft-Gault equation: CrCl = [(140 − age) × weight] / [72 × S_Cr]. Substituting: CrCl = [(140 − 80) × 68] / [72 × 1.4] = [60 × 68] / [100.8] = 4080 / 100.8.

CrCl ≈ 40.5 mL/min
2
Step 2 — Assess Renal Function Category

A CrCl of 40.5 mL/min indicates moderate renal impairment (CKD Stage 3b, corresponding to a GFR of 30–44 mL/min/1.73 m²). This is significantly below the normal value of approximately 120 mL/min in a young adult.

Moderate renal impairment — dose reduction required
3
Step 3 — Calculate the Dose Adjustment Fraction

For a drug that is 85% renally cleared, the dose adjustment factor accounts for the fraction of normal renal function retained. Using a simplified proportional approach: Adjusted fraction = (patient CrCl / normal CrCl) = 40.5 / 120 ≈ 0.34 for the renal component. The total adjustment factor = (1 − renal fraction) + (renal fraction × patient CrCl / normal CrCl) = (0.15) + (0.85 × 0.34) = 0.15 + 0.289 ≈ 0.44.

Adjustment factor ≈ 0.44
4
Step 4 — Calculate Adjusted Dose

Adjusted dose = standard dose × adjustment factor = 0.25 mg × 0.44 = 0.11 mg. Since digoxin is available in 0.125 mg tablets, the practical adjusted dose would be 0.125 mg/day, which aligns with the Beers Criteria recommendation of ≤0.125 mg/day in older adults.

Adjusted dose = 0.125 mg/day (half the standard adult dose)
5
Step 5 — Plan for Monitoring

Order a serum digoxin level 5–7 days after initiation (approximately 5 half-lives to reach steady state). Target a trough concentration of 0.5–0.9 ng/mL. Monitor serum potassium, magnesium, and renal function concurrently, as electrolyte abnormalities potentiate digoxin toxicity. Reassess the need for digoxin periodically.

Target serum digoxin: 0.5–0.9 ng/mL

SECTION 7

ADR Risk Factors & Mitigation Strategies

Adverse drug reactions in the elderly are not random misfortunes; they are frequently predictable consequences of specific, identifiable risk factors. Studies suggest that patients over 65 are two to three times more likely to experience ADRs than younger adults, and that up to 30% of hospital admissions in this age group are drug-related. Effective geriatric prescribing involves systematically identifying and mitigating these risk factors.

Risk Factor	Mechanism of Harm	Mitigation Strategy
Polypharmacy (≥5 medications)	Exponential increase in drug–drug interactions; each additional drug increases ADR risk by approximately 12–18%	Regular medication reconciliation; deprescribing protocols; use of interaction-checking software
Reduced renal clearance	Accumulation of parent drugs and active metabolites, especially with narrow therapeutic index agents	Estimate CrCl using Cockcroft-Gault; adjust doses per renal dosing guidelines; avoid nephrotoxic combinations
Altered body composition	Increased fat stores extend half-life of lipophilic drugs; decreased total body water raises concentration of hydrophilic drugs	Use ideal or adjusted body weight for dosing; prefer shorter-acting agents when possible
Cognitive impairment	Non-adherence (missed or duplicated doses); inability to recognize or report ADR symptoms	Simplify regimens; use pill organizers; involve caregivers; schedule medication reviews
Prescribing cascades	ADR of one drug is misdiagnosed as a new condition, triggering additional unnecessary medications	Always ask: 'Could this new symptom be a drug side effect?' before adding therapy

Common ADR risk factors in older adults with corresponding clinical strategies

✦

KEY TAKEAWAY

Think of geriatric medication management like managing a complex flight system. Each additional instrument (drug) added to the cockpit increases the total system complexity and the probability that warning signals will be missed or misinterpreted. A good pilot—and a good clinician—periodically strips back to essentials, removing unnecessary gauges to keep the critical ones visible. In pharmacology, this process is called deprescribing: the systematic, evidence-based discontinuation of medications that are no longer necessary or whose risks now outweigh their benefits.

SECTION 8

Pharmacogenomics & the Future of Geriatric Prescribing

The principles of geriatric pharmacology discussed thus far address population-level trends, but the future of the field lies in individualization. Pharmacogenomics—the study of how genetic variation influences drug response—adds a critical layer of precision to age-based dosing adjustments. In older adults, genetic polymorphisms in CYP450 enzymes (particularly CYP2D6, CYP2C19, and CYP3A4) interact synergistically with age-related declines in hepatic function, creating highly variable drug metabolism profiles even among individuals of the same age and weight. For example, a geriatric patient who is a CYP2D6 poor metabolizer may experience toxicity from codeine at doses that are subtherapeutic for an ultra-rapid metabolizer of the same age.

Feature	Traditional Geriatric Dosing	Pharmacogenomics-Guided Dosing
Approach	Population-based empiric adjustments (age, weight, renal function)	Individualized dosing based on genotype + phenotype + age-related physiology
CYP450 metabolism	Assumed to decline uniformly with age; general dose reductions recommended	Specific metabolizer phenotype (poor/intermediate/normal/ultra-rapid) guides drug and dose selection
Drug selection	Beers Criteria excludes classes; substitution based on clinical guidelines	Gene-drug interaction data (e.g., CPIC guidelines) refine choices within classes
Monitoring	Serum drug levels, clinical assessment, periodic CrCl measurement	Preemptive genotyping + therapeutic drug monitoring + clinical assessment
Limitations	Treats all elderly as a homogeneous group; may over- or under-adjust	Cost, limited access, incomplete evidence for many drug-gene pairs in elderly

Traditional vs. pharmacogenomics-guided prescribing in older adults

Looking ahead, the integration of artificial intelligence-driven clinical decision support systems with pharmacogenomic data and real-time renal function monitoring promises to transform geriatric prescribing from reactive (adjusting after ADRs occur) to truly predictive and preventive. Additionally, ongoing research into the concept of biological age versus chronological age aims to replace the crude threshold of '65 and older' with more nuanced assessments of physiological reserve, allowing even more precise individualization of pharmacotherapy.

SECTION 9

Practice Problems

Question 1: CONCEPTUAL

Explain why the half-life of diazepam (a highly lipophilic benzodiazepine) is significantly longer in an 80-year-old patient compared to a 25-year-old, even if both have similar hepatic enzyme activity. Reference both pharmacokinetic parameters that determine half-life.

Show answer

Half-life is determined by the equation t½ = (0.693 × V_d) / CL. In the elderly patient, the volume of distribution (V_d) for lipophilic drugs like diazepam increases substantially because aging is associated with a higher proportion of adipose tissue relative to lean body mass. Diazepam partitions extensively into fat compartments, effectively expanding its V_d. Even if clearance (CL) remains similar, the larger V_d in the numerator directly increases t½. In reality, hepatic blood flow also typically declines with age, further reducing CL and compounding the effect. The result is that diazepam's half-life may extend from approximately 24 hours in a young adult to 90+ hours in an octogenarian, explaining the prolonged sedation and increased fall risk.

Question 2: BASIC CALCULATION

A 75-year-old female patient weighs 55 kg and has a serum creatinine of 1.2 mg/dL. Using the Cockcroft-Gault equation, calculate her estimated creatinine clearance.

Show answer

Applying the Cockcroft-Gault equation: CrCl = [(140 − 75) × 55] / [72 × 1.2] × 0.85 (female correction). Step by step: (140 − 75) = 65; 65 × 55 = 3575; 72 × 1.2 = 86.4; 3575 / 86.4 = 41.4 mL/min; 41.4 × 0.85 = 35.2 mL/min. The estimated CrCl is approximately 35 mL/min, indicating moderate-to-severe renal impairment (CKD Stage 3b). This patient would require dose reductions for renally cleared drugs such as digoxin, lithium, aminoglycosides, and gabapentin. Note that despite a 'near-normal' serum creatinine of 1.2, her actual renal function is substantially impaired—illustrating why serum creatinine alone is misleading in geriatric patients.

Question 3: INTERMEDIATE

A 78-year-old man with heart failure, osteoarthritis, type 2 diabetes, and benign prostatic hyperplasia is currently taking lisinopril, metformin, tamsulosin, and aspirin. His physician is considering adding ibuprofen for joint pain and oxybutynin for urinary frequency. Analyze the appropriateness of each proposed addition using geriatric pharmacology principles.

Show answer

Both proposed additions are problematic. Ibuprofen (an NSAID) is on the Beers Criteria for older adults with heart failure because it promotes sodium and water retention, can exacerbate fluid overload, and antagonizes the beneficial effects of lisinopril (ACE inhibitor). Additionally, the combination of ibuprofen with aspirin may reduce aspirin's cardioprotective antiplatelet effect through competitive COX-1 binding, and increases GI bleeding risk. NSAIDs also reduce renal perfusion, which is particularly dangerous in a patient already on an ACE inhibitor. Oxybutynin is a first-generation anticholinergic flagged on the Beers Criteria due to high anticholinergic burden—especially hazardous in elderly patients with reduced cholinergic reserve. It causes confusion, constipation, dry mouth, blurred vision, and urinary retention (paradoxically worsening the condition it treats in some patients). Furthermore, his urinary frequency should be re-evaluated: it may be secondary to tamsulosin's mechanism or his diabetes. Safer alternatives include topical NSAIDs or acetaminophen for pain and mirabegron (a beta-3 agonist with lower anticholinergic burden) if pharmacological treatment for overactive bladder is truly needed.

Question 4: APPLIED

An 82-year-old nursing home resident with mild dementia is found confused and lethargic. She was recently started on a new sleep medication. Her medication list includes: donepezil 10 mg (for dementia), diphenhydramine 50 mg at bedtime (newly prescribed for insomnia), metoprolol 25 mg (for hypertension), and omeprazole 20 mg (for GERD). Identify the most likely cause of her acute change in mental status, explain the pharmacological mechanism, and propose a management plan.

Show answer

The most likely culprit is diphenhydramine, a first-generation antihistamine with potent anticholinergic activity. In this patient, diphenhydramine creates a direct pharmacodynamic conflict: donepezil is a cholinesterase inhibitor that increases acetylcholine availability in the CNS to support cognition, while diphenhydramine is a muscarinic receptor antagonist that blocks acetylcholine signaling. The combination effectively negates the therapeutic benefit of donepezil. Furthermore, diphenhydramine's anticholinergic effects are amplified in the elderly due to the age-related decline in central cholinergic neurotransmission (reduced cholinergic reserve), causing confusion, sedation, and potential delirium. The 50 mg dose is inappropriately high for an elderly patient, as decreased hepatic CYP2D6 activity may prolong the drug's duration of action. Management should include: (1) immediate discontinuation of diphenhydramine; (2) monitoring for resolution of confusion over 24–48 hours; (3) evaluation for non-pharmacological sleep interventions (sleep hygiene education, environmental modifications); (4) if pharmacotherapy for insomnia is necessary, consider low-dose melatonin or trazodone, which have lower anticholinergic burden; (5) documentation of this event and patient education to prevent future prescribing of anticholinergics.

Question 5: CRITICAL THINKING

The 'start low, go slow' principle is widely endorsed in geriatric pharmacology. However, some clinical situations demand rapid dose escalation or full-dose initiation even in elderly patients. Identify two such clinical scenarios, explain why the standard geriatric approach must be modified, and describe what safeguards should be implemented when deviating from the conservative dosing paradigm.

Show answer

Two scenarios where 'start low, go slow' may be inappropriate include: (1) Acute life-threatening infections requiring antibiotics. In severe sepsis, pharmacokinetic modeling demonstrates that subtherapeutic antibiotic concentrations during the first 24–48 hours are associated with significantly increased mortality. For drugs like vancomycin or piperacillin-tazobactam, loading doses should be based on actual clinical need rather than empirically reduced for age alone. In this scenario, the consequence of under-dosing (treatment failure, death) far outweighs the risk of transient ADRs. (2) Acute decompensated heart failure requiring intravenous diuretics. Elderly patients presenting with pulmonary edema need rapid fluid removal. Initiating furosemide at low doses and titrating slowly could result in respiratory failure. Full or even supra-normal doses may be necessary, recognizing that chronic diuretic use often creates diuretic resistance requiring higher thresholds. Safeguards when deviating from conservative dosing include: intensive clinical monitoring (telemetry, frequent vitals, input/output tracking); therapeutic drug monitoring when available (vancomycin troughs, digoxin levels); serial laboratory assessment (renal function, electrolytes, hepatic function); explicit documentation of the risk-benefit rationale; planned de-escalation protocols once the acute crisis resolves; and multidisciplinary team involvement (clinical pharmacist review, geriatrics consultation). The key insight is that 'start low, go slow' is a default principle, not an absolute rule—clinical judgment must weigh the risks of under-treatment against over-treatment in each individual patient context.

SUMMARY

Geriatric Pharmacology — Key Concepts Review

Summary

Geriatric pharmacology addresses the systematic impact of aging on drug therapy, recognizing that pharmacokinetic changes—including increased gastric pH, expanded volume of distribution for lipophilic drugs, decreased hepatic Phase I metabolism, and declining glomerular filtration rate—collectively produce higher effective drug concentrations and prolonged half-lives in older adults. Simultaneously, pharmacodynamic changes alter receptor sensitivity and homeostatic reserve, making elderly patients more vulnerable to both exaggerated therapeutic effects and adverse drug reactions. The Cockcroft-Gault equation remains a critical tool for estimating renal function and guiding dose adjustments, particularly because serum creatinine alone is unreliable in this population.

Clinical management rests on several pillars: the start low, go slow dosing principle, avoidance of potentially inappropriate medications identified by the Beers Criteria, recognition and prevention of prescribing cascades, systematic deprescribing to reduce polypharmacy, and individualized monitoring using therapeutic drug levels and renal function estimates. Looking forward, pharmacogenomics promises to refine these population-based strategies with genotype-driven precision, ultimately transforming geriatric prescribing from empiric dose reduction to truly individualized pharmacotherapy.